Market research
TELA Tela Bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 2.1
- Dividend yield
- Not available
- Beta
- 1.36
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US8723811084
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 2.1
- Dividend yield
- Not available
- Beta
- 1.36
About
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TELA discussion.
5 years, 4 months ago
TELA Bio, Inc is currently in a long term uptrend where the price is trading 4.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.9.
TELA Bio, Inc's total revenue rose by 16.5% to $6M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-8K since the same quarter in the previous year.
Finally, its free cash flow grew by 1.0% to $-7M since the same quarter in the previous year.
Based on the above factors, TELA Bio, Inc gets an overall score of 5/5.